We understand how important it is to know if your test material of interest adversely affects the chemistry, structure, or function of the nervous system. With this need in mind, the neurotoxicology program at Charles River encompasses a broad range of products, including pharmaceuticals, biopharmaceuticals, biologics, and chemicals in both rodent and nonrodent species. With over two decades of experience, we have valuable historical control databases.
Check out our poster presentations from the Society of Toxicology's 2018 annual meeting.
Charles River has a knowledgeable staff of scientists and technical personnel who routinely perform neurotoxicity screening tests for possible on- or off-target effects, specialized target tissue delivery, expanded investigative studies, and developmental neurotoxicity, and any preclinical study that requires the analysis of abuse and dependence liability potential.
- Neurobehavior, including assays of locomotor activity, rotarod forced activity, water maze learning and memory testing, auditory startle habituation, and functional observational batteries
- Abuse liability testing with any drug that crosses the blood-brain barrier regardless of therapeutic indication
- Ototoxicity testing, GLP-compliant and measuring auditory function, cytocochleogram, otic histology, and evaluation of potential recovery
- Neurochemistry, including cholinesterase assays in red blood cell, plasma, and brain samples, as well as quantification of endogenous levels of neurotransmitters
- Neuropathology, including in situ perfusion, morphometry, stereology, and qualitative neuropathological evaluations
- Acute neurotoxicity
- Subchronic neurotoxicity
- Developmental neurotoxicity
- Behavioral developmental toxicity
- Safety pharmacology
- NMDA receptor antagonist
- Standard dose routes
- Routine and specialized routes of parenteral injection or infusion and target-tissue administration